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ABSTRACT 
Objective: Depression is one of the most common mood disorders. Patients with major depressive disorder (MDD) usually present alterations in 
various cognitive functions. Several cost-effective interventions have shown favorable recovery and positive outcomes in the care and management 
of depression. The objective of the study was to compare the effect of fluoxetine (selective serotonin reuptake inhibitors), and venlafaxine (serotonin-
norepinephrine reuptake inhibitors) on cognitive functioning in patients with MDD.
Methods: This prospective, single-blinded, randomized, and comparative interventional clinical study was conducted in a tertiary care hospital in 
Haryana. Fifty-two patients of MDD (ICD-10) were randomly divided into two groups: Group F and Group V, allocated to receive fluoxetine and 
venlafaxine, respectively. The assessment was done during the enrolment and at the end of the 3rd, 6th, 9th, and 12th weeks of treatment using the ABC-
Hamilton Depression Rating Scale (HAM-D) and Montreal Cognitive Assessment (MoCA) Scale.
Statistical Analysis Used: The intragroup analysis was performed using repeated measures ANOVA while intergroup analysis was performed using 
unpaired “t”-test. p<0.05 was considered statistically significant. 
Results: Mean HAM-D score was clinically as well as statistically significant at the end of the 12th week of treatment as compared to baseline in both 
the groups while on the intergroup comparison, there was no statistically significant difference in both groups. The mean MoCA score was (25±2.19) 
in Group F and (23.76±6.97) in Group V at the end of the 12th week. On intergroup analysis at the 12th week, a statistically significant improvement in 
cognitive functions was observed in patients Group F as compared to Group V (p<0.05).
Conclusions: The study of fluoxetine comparatively better improves cognition functions as compared to venlafaxine. 
Keywords: Hamilton depression rating scale, Montreal cognitive assessment scale, Fluoxetine and venlafaxine.
INTRODUCTION
Globally, in 2015, an estimated 322 million people were affected by 
depression. India is home to an estimated 57 million people (18% 
of the global estimate) affected by depression [1]. Depression is the 
main cause of illness and disability among the young and middle-aged 
population. Patients with major depressive disorder (MDD) usually 
present with alterations in various cognitive functions [2,3]. It often 
results in impaired functioning, which has an impact on all aspects of 
an individual’s life and family [4]. Depression is largely preventable 
and treatable. Several cost-effective interventions have shown 
favorable recovery and positive outcomes in the care and management 
of depression. The treatment options include non-pharmacological 
therapies and pharmacological therapies [5]. However, the best results 
are seen with non-pharmacological therapies in conjunction with 
pharmacological therapy. 
Pharmacotherapy includes monoamine oxidase inhibitors (MAOIs) 
and tricyclic antidepressants (TCAs), selective serotonin reuptake 
inhibitors (SSRIs), for example, fluoxetine, serotonin-norepinephrine 
reuptake inhibitors (SNRIs), for example, venlafaxine. The SSRIs and 
SNRIs have proven greater efficacy and safety than the TCAs and 
MAOIs [6]. The efficacy can be measured as changes from baseline or 
remission on an investigator-rated diagnostic depression scale such 
as the Hamilton Depression (HAM-D) Rating Scale for depression. The 
effects of antidepressant medications on cognition are an important, 
yet surprisingly understudied question. Moreover, the limited literature 
evaluating this question may be restricted because these evaluations 
are not typically conducted from a neuropsychological perspective 
that includes a comprehensive assessment of cognitive domains of 
executive functioning, attention, concentration, psychomotor speed, 
memory, and verbal and visuospatial memory, a radical understanding 
of cognitive effects of antidepressant medications remains unknown. 
Hence, the present study was aimed at comparing the effect of different 
antidepressants, fluoxetine, and venlafaxine on cognition functioning in 
patients with MDD in tertiary care hospital, Haryana.
METHODS
This prospective, single-blinded randomized, and comparative clinical 
study was done as per the principles of good clinical practice (ICH-
GCP) and the Declaration of Helsinki. The study was conducted after 
obtaining ethical clearance from the institutional ethics committee 
(IEC). Patients with MDD were screened and selected as per the 
inclusion and exclusion criteria for this study. 
Newly diagnosed patients with severe/major depression (according to 
ICD-10) [7], of either sex between the age of 18 and 69 years, having 
a minimum educational qualification up to fifth class were included 
and those who were having a history of substance abuse and on any 
other medications, with any other psychiatric illness or any other 
central nervous system and systemic disorder that are known to affect 
cognition and psychomotor functions were excluded from the study. A 
patient information sheet was provided to every eligible subject for the 
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study and thereafter a written informed consent was taken from the 
subjects.
The eligible subjects were randomly divided into two groups, 30 in 
each group who received one of the following treatments for 12 weeks. 
Group F patients received fluoxetine (20–40 mg) and Group V has 
received venlafaxine (75–150 mg) provided from the hospital supply. 
Starting doses of fluoxetine and venlafaxine were 20 mg and 75 mg, 
respectively. Drug doses may be adjusted depending on the symptoms 
of patients during subsequent follow-up. 
Groups F and V also received Clonazepam 0.5 mg for an initial 2 weeks 
in addition to studying drugs. It was given to control the symptoms 
because of the lag period of antidepressants to shows their clinical 
effects. Therefore, the initial assessment of the patient was done on 
day 0, that is, on the day of enrolling the patient, and the subsequent 
assessment of the patient was done after the clonazepam washes out 
from the system completely, that is, at the end of 3rd, 6th, 9th, and 12th 
weeks. All the subjects were assessed with the ABC version Hamilton 
Depression Rating Scale (HAM-D) [8] and the Montreal Cognition 
Assessment Scale (MoCA) [9].
Primary end points
ABC version HAM-D
HAM-D developed by Max Hamilton in 1960 is a multiple item 
questionnaire used to indicate depression, and as a guide to evaluating 
recovery. The questionnaire is meant for adults and is employed to 
rate the severity of their depression. The theoretical score range of the 
whole HAM-D17 goes from 0 to 52. For the HAM-D17, a score of 0–7 is 
generally accepted to be within the normal range or the patient is in the 
clinical remission phase, while a score of 20 or higher indicating at least 
moderate severity of the depression.
Montreal cognitive assessment (MoCA)
The MoCA is meant as a rapid screening instrument for mild cognitive 
dysfunction. It contains eight questions that assessed different cognitive 
domains: attention and concentration, executive functions, memory, 
language, visuoconstructional skills, conceptual thinking, calculations, 
and orientation. Each patient was given a maximum of 10 min to complete 
the test. MoCA comprises 30 points and the normal score is considered to 
be 26 and above and it has good reliability for repeated assessment [10].
Statistical analysis 
Data were expressed as mean±SEM unless specified otherwise. Both 
intragroup and intergroup statistical analysis was performed. The 
intragroup analysis was performed using repeated measures ANOVA 
while intergroup analysis was performed using unpaired “t” test. 
p<0.05 was considered statistically significant.
RESULTS
The demographic profile of the patients in the two study groups was 
comparable, as shown in Table 1. The average age in Group F was 
32.46±12.59 and Group V was 37.23±11.03 in years. The total male to 
female ratio of the patients involved in the study was 1.73:1 (Fig. 1).
Clinical assessment of depression in the Group-F, mean HAM-D score 
at baseline and 3rd, 6th, 9th, and 12th weeks was 20.11±2.51, 17.23±2.91, 
14.30±4.89, 10.57±3.16, and 8.30±2.73, respectively. In Group V, the 
mean score was 20.57±2.74, 17.84±2.96, 15.07±3.24, 12±2.99, and 
9.46±2.91, respectively (Table 2). The mean HAM-D score in Group F 
and Group V at different time intervals is shown in Fig. 2. 
On intragroup comparison in both the groups at 3rd, 6th, 9th, and 12th 
weeks intervals from the baseline, the results were statistically 
significant (p<0.05). However, on intergroup analysis, the mean HAM-D 
score was compared between Group F and Group V; it was observed 
that the difference in mean HAM-D score at 3rd, 6th, 9th, and 12th weeks 
interval was clinically as well as statistically nonsignificant.
Table 1: Demographic details
Variable Group F(n=26) Group V (n=26)
Mean age 32.46±12.59 37.23±11.03
Gender (M: F) 1.77: 1 1.7: 1
Table 2: Intergroup comparison of Hamilton depression rating 
scale in Group F (n=26) and Group V (n=26)
Time interval Group F Group V p value
Baseline 20.11±2.51 20.57±2.74 0.26
3rd week 17.23±2.91 17.84±2.96 0.22
6th week 14.30±4.89 15.07±3.24 0.25
9th week 10.57±3.16 12±2.99 0.50
12th week 8.30±2.73 9.46±2.91 0.07
Fig. 1: Pie chart showing gender distribution of major depressive 
disorder patients
Fig. 2: Intergroup and intragroup comparison of Hamilton 
depression rating scale score in Group F and Group V
Cognitive functions were assessed using MoCA Scale at baseline 
and the end of 3rd, 6th, 9th, and 12th weeks MoCA scores in Group F 
was 17.07±2.41, 19.23±1.92, 21.53±2.21, 23.46±2.70, and 25±2.19, 
respectively, and in the Group-V, mean MoCA score was 15.34±2.52, 
17.73±2.29, 19.76±2.29, 21.88±2.30, and 23.76±6.97, respectively 
(Table 3). The mean MoCA score in Group F and Group V at different 
time intervals is shown in Fig. 3.
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On intragroup comparison in both the groups at 3rd, 6th, 9th, and 12th 
weeks intervals from the baseline, the results were statistically 
significant (p<0.05). However, on intergroup analysis, the mean MoCA 
score was compared between Group F and Group V, it was observed 
that the difference in mean MoCA score at 3rd, 6th, and 9th weeks interval 
was clinically as well as statistically nonsignificant but at the end of 
12th weeks of treatment Group F showed a statistically significant 
improvement in cognitive functions as compared to Group V (p<0.05).
DISCUSSION
The management of depressive patients for improvement of cognitive 
functions remains an area for never-ending research with better 
formulations and modalities continuously replacing present ones. 
Impairment of cognition functions is commonly reported in individuals 
with MDD. This study was done to evaluate the effect of SSRI and SNRI, 
that is, fluoxetine (20–40 mg) and venlafaxine (75–150 on cognition in 
patients with MDD. Each study group had 26 patients of either sex between 
18 and 69 years was completed the study. The mean age was 32.46±12.59 
years in Group F, and 37.7±11.03 years in Group V. The observations of 
this study showed that there was no statistically significant difference 
between the ages of patients in both the groups (p>0.05). In this study, 
there were approximately 60% males and 40% females. The overall male 
to female patient ratio was 1.73:1. Jaykaran et al. [11] and Ghodke et al. [10] 
conducted a similar study which showed a demographic profile of having 
58% of male, 45% of female and 55% of male, 45% of female, respectively. 
However, some studies do not corelate with this male-female ratio. It 
completely depends on the area in which the study is conducted rural and 
urban due to which the male-female ratio differs.
HAM-D was taken used to evaluate the severity of depression and also 
to evaluate recovery from depression. In the present study, the mean 
HAM-D score was compared between Group F and Group V at baseline, 
end of 3rd, 6th, 9th, and 12th weeks. In Group-F, mean HAM-D scores at 
the different intervals were 20.11±2.51, 17.23±2.91, 14.30±4.89, 
10.57±3.16, and 8.30±2.73, and in the Group-V, mean HAM-D scores 
were 20.57±2.74, 17.84±2.96, 15.07±3.24, 12±2.99, and 9.46±2.91. 
Both drugs were found to be equally efficacious. The patients treated 
with fluoxetine and venlafaxine showed a significant reduction in scores 
at the end of every follow-up as compared to the baseline. On intergroup 
analysis, the mean HAM-D score was compared between Group F and 
Group V; it was observed that the difference in mean HAM-D score at 
3rd, 6th, 9th, and 12th weeks interval was clinically as well as statistically 
nonsignificant. A similar study was conducted by Mendhe et al. [12], 
study revealed that on comparing the efficacy of the antidepressants, 
all the groups showed a significant reduction in mean scores at the 
end of the 1st month and 3rd month as compared to the baseline values. 
However, no statistically significant difference was observed at the end 
of 3 months of treatment among the different groups. Wagner et al. [13] 
observed that the HAM-D score was statistically significant in an 8-week 
study while comparing escitalopram, venlafaxine, and lithium. Few other 
studies showed similar results in the HAM-D score while comparing 
different antidepressants [14-17]. In this study, we also observed that 
both the drugs are efficacious in improving the symptoms of depression 
from 3 weeks onward with progressive improvement till the end of the 
study. Thus, both the antidepressant drugs were well tolerated and 
equally efficacious in improving symptoms of depression. 
Cognitive functions were assessed using the MoCA. The difference in 
the values between baseline and at the end of the study period was 
calculated and compared. In our study, the mean score of MoCA in Group 
F at different interval, that is, at the end of 3rd, 6th, 9th, and 12th weeks from 
the baseline (17.07±2.4) was 19.23±1.92, 21.53±2.21, 23.46±2.70, and 
25±2.19, respectively. In Group V, the mean score of MoCA at different 
interval, that is, at the end of 3rd, 6th, 9th, and 12th weeks from the baseline 
(15.34±2.52) was 17.73±2.29, 19.76±2.29, 21.88±2.30, and 23.76±6.97, 
respectively. Up to my knowledge, no previous study was found using 
MoCA for cognitive assessment in different classes of antidepressants 
but studies were there which showed an effect on cognition in patients 
of MDD. The present study used this scale as it was assessed several 
cognitive domains at first time and was a more sensitive tool to assess 
cognition, especially mild cognition deficit. We observed clinically as 
well as statistically improvement in the mean MoCA scores at the end 
of 3rd, 6th, 9th, and 12th weeks from the baseline in both the groups at a 
different time interval, that is, p<0.05. On intergroup analysis, the mean 
MoCA score at 3rd, 6th, and 9th weeks interval was clinically as well as 
statistically nonsignificant but at the end of the 12th week of treatment 
Group F showed a statistically significant improvement in cognitive 
functions as compared to Group V (p<0.05).
The strengths of the present study were that we used standard, 
validated scales during our study for assessing cognition functioning in 
patients of MDD. To the best of our knowledge, no studies had assessed 
Cognition using Montreal Cognitive scale which was more sensitive 
than Mini-Mental Scale [18,19] but some studies showed the impact 
of depressive symptomatology on the MoCA as a cognitive screening 
tool [20]. In our study, it is used for the first time to compare the effect 
of different classes of antidepressants on cognitive functioning and with 
a different mechanism of action which helps us to know more about 
the role of neurotransmitters in cognition improvement. However, our 
study had some limitations also. The number of patients enrolled in 
each group was less. A strict inclusion criterion for patients suffering 
only from endogenous depression not associated with any other 
comorbidity and concomitant medication was excluded from the study. 
Second, the duration of the study was short, and we could not follow 
the patients until the complete remission of the disease. Significant 
limitations were the heterogeneity of results
However, the importance of the present study cannot be undermined. 
Studies are available which show the effect of antidepressants on 
cognitive functions but most of these studies are single-dose studies, 
and studies of the same class of antidepressants [21].
CONCLUSION 
The findings of this study provide insight into the fact that 
antidepressant medications affect several areas of cognition, 
Table 3: Intergroup comparison of Montreal cognitive 
assessment scale in Group F (n=26) and Group V (n=26) 
Time interval Group F Group V p value
Baseline 17.07±2.41 15.34±2.52 0.007*
3rd week 19.23±1.92 17.73±2.29 0.006
6th week 21.53±2.21 19.76±2.29 0.003*
9th week 23.46±2.70 21.88±2.30 0.013
12th week 25±2.19 23.76±6.97 0.029
Fig. 3: Intergroup and intragroup comparison of Montreal 
cognitive assessment score in Group F and Group V
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including processing speed, attention, and some areas of learning 
and memory. Our study suggests that both the SSRI and SNRI classes 
of antidepressant drugs are equally effective in the treatment 
of depression when compared to baseline along with improving 
cognition functioning. Fluoxetine significantly improves cognition 
functions as compared to venlafaxine.
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Hamilton Depression Rating Scale (HAM-D) also HDRS or HRSD
PatientName:__________________________________________Date:_____________________
Instructions:  For each item select the “cue” which best characterizes the patient during the past 
week.




1  These feeling states indicated only on 
questioning
2  These feeling states spontaneously reported 
verbally
3  Communicates feeling states nonverbally, i.e., 
through facial expression, posture, voice and 
tendency to weep
4  Patient reports VIRTUALLY ONLY these 
feeling states in his spontaneous verbal and 
nonverbal communication
0 None
1 “Playing with” hand, hair, etc.
2 Hand-wringing, nail-biting, biting of 
lips
10. Anxiety – Psychic
0 No difficulty
1 Subjective tension and irritability
2 Worrying about minor matters
3  Apprehensive attitude apparent in face 
or speech
4 Fears expressed without questioning2. Feelings of Guilt
0 Absent
1 Self-reproach, feels he has let people down
2  Ideas of guilt or rumination over past errors 
or sinful deeds
3  Present illnesses are a punishment. 
Delusions of guilt
4  Hears accusatory or denunciatory voices 
and/or experiences threatening visual 
hallucinations






Physiological concomitants of 
anxiety such as:
Gastrointestinal – dry mouth, wind, 
indigestion,
diarrhea, cramps, belching
Cardiovascular – palpitations, 
headaches






1 Feels life is not worth living
2  Wishes he were dead or any thoughts of 
possible death to self
3 Suicide ideas or gesture
4  Attempts at suicide (any serious attempt 
rates 4)
12. Somatic Symptoms – Gastrointestinal
0 None
1  Loss of appetite but eating without staff 
encouragement.
2  Difficulty eating without staff urging. 
Requests or requires laxatives or 
medications for bowels or medication 
for G.I. symptoms.
4. Insomnia – Early 13. Somatic Symptoms – General
0 No difficulty falling asleep
1  Complains of occasional difficulty falling 
asleep i.e., more than ½ h
2  Complains of nightly difficulty falling asleep
0 None
1  Heaviness in limbs, back or head, 
backaches, headache, muscle aches, loss 
of energy and fatigability
2 Any clear-cut symptom rates 2
5. Insomnia - Middle 14. Genital Symptoms
0 No difficulty
1  Patient complains of being restless and 
disturbed during the night
2  Waking during the night – any getting out of 




0 Not ascertained symptoms 
such as: loss of libido, menstrual 
disturbances
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6. Insomnia – Late 15. Hypochondriasis
0 No difficulty
1  Waking in early hours of the morning but 
goes back to sleep
2  Unable to fall asleep again if gets out of bed
0 Not present
1 Self-absorption (bodily)
2 Preoccupation with health
3 Frequent complaints, requests for help, 
etc.
4 Hypochondriacally delusions
7. Work and Activities
0 No difficulty
1  Thoughts and feelings of incapacity, fatigue 
or weakness related to activities; work or 
hobbies
2 Loss of interest in activity; hobbies or 
work – either directly reported by patient, 
or indirect in listlessness, indecision and 
vacillation (feels he has to push self to work or 
activities)
3 Decrease in actual time spent in activities 
or decrease in productivity. In hospital, rate 3 
if patient does not spend at least 3 h a day in 
activities (hospital job or hobbies) exclusive of 
ward chores.
16. Loss of Weight
A. When Rating by History:
0 No weight loss
4 Stopped working because of present illness. 
In hospital, rate 4 if patient engages in no 
activities except ward chores, or if patient fails 
to perform ward chores unassisted.
1  Probable weight loss associated with 
present illness
2  Definite (according to patient) weight 
loss
8. Retardation (slowness of thought and 
speech; impaired ability to concentrate; 
decreased motor activity)
0 Normal speech and thought
1 Slight retardation at interview




0 Less than 1 lb. weight loss in week
1>1 lb. weight loss in week
2>2 lb. weight loss in week
17. Insight
0 Acknowledges being depressed and ill
1  Acknowledges illness but attributes 
cause to bad food, climate, overwork, 
virus, need for rest, etc.
2 Denies being ill at all
Total Score:_____________________
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